Segmental vitiligo following acitretin treatment for infantile generalized pustular psoriasis resulting in repigmentation under secukinumab therapy

Yang, Yijun; Xu, Qianyue; Zhang, Zhen; Yao, Zhirong

doi:10.1111/dth.15305

Cited by 2 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secukinumab is a fully human immunoglobulin‐Gκ IL‐17A monoclonal antibody and decreases IL36R activation by inhibiting IL‐17A and disturbing the inflammatory loop of GPP. Several cases and case series have described the efficacy and safety of secukinumab 19,57–66 . Our team reviewed the efficacy and adverse events of secukinumab in 20 Chinese pediatric patients with GPP, with the ages ranging from 6 to 12 years and the age of onset ranging from 2 months to 11 years 19 .…”

Section: Systemic Treatmentsmentioning

confidence: 99%

“…Several cases and case series have described the efficacy and safety of secukinumab. 19 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 Our team reviewed the efficacy and adverse events of secukinumab in 20 Chinese pediatric patients with GPP, with the ages ranging from 6 to 12 years and the age of onset ranging from 2 months to 11 years. 19 All the children had improvement in symptoms in the first week, and all patients achieved a JDA severity index of 0/1 in 3 weeks.…”

Section: Systemic Treatmentsmentioning

confidence: 99%

See 1 more Smart Citation

The update of treatment strategies in pediatrics with generalized pustular psoriasis in China

Chen,

Xiang,

Wang

et al. 2023

Pediatric Investigation

View full text Add to dashboard Cite

Generalized pustular psoriasis (GPP) is a severe subtype of psoriasis, commonly combined with systemic inflammation. Gene mutations have been found to be associated with GPP and vary by ethnicity. Systemic treatments are usually required for the severity and potential complications of GPP. However, there is no common consensus in China, especially among pediatric patients, whose data are scarce. Acitretin, methotrexate, and cyclosporine are widely used in pediatrics with GPP, while the adverse effects should be highlighted. The emergence of different biological agents brings us into a new era. This article discusses the genetic background of Chinese patients and demonstrates the evidence of treatment in pediatrics with GPP.

show abstract

Section: Systemic Treatmentsmentioning

confidence: 99%

Section: Systemic Treatmentsmentioning

confidence: 99%

The update of treatment strategies in pediatrics with generalized pustular psoriasis in China

Chen,

Xiang,

Wang

et al. 2023

Pediatric Investigation

View full text Add to dashboard Cite

show abstract

“…A 63-year-old man with psoriasis who developed vitiligo during therapy with adalimumab showed near complete repigmentation after one year of secukinumab administration [48]. Moreover, a 1-year-old boy with generalized pustular psoriasis developed generalized vitiligo after three weeks of acitretin treatment that improved with secukinumab in combination with topical steroid [49]. Gradual repigmentation of the face and trunk was observed from the fifth and twelfth administration of secukinumab, respectively, while no significant improvement was observed on the scalp.…”

Section: Biologicsmentioning

confidence: 99%

Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics

Pala,

Ribero,

Quaglino

et al. 2023

JCM

View full text Add to dashboard Cite

Vitiligo, the most prevalent skin depigmenting disease, is characterized by the selective loss of melanocytes, impacting patients’ quality of life significantly. This autoimmune disorder progresses through a complex interplay of genetic and non-genetic factors, posing challenges in comprehending its pathogenesis and devising effective treatment strategies for achieving remission. Existing conventional therapeutic approaches, such as topical and oral corticosteroids, calcineurin inhibitors, and phototherapy, lack specificity, offer modest efficacy, and may entail potential adverse effects. Consequently, there is a pressing need for a more nuanced understanding of vitiligo’s pathogenesis to pave the way for targeted therapeutic innovations. This review aims to provide a comprehensive overview of recent developments and findings concerning Januse Kinase (JAK) inhibitors and biologics tested in vitiligo patients. JAK inhibitors have exhibited promising results, showcasing both efficacy and tolerability. In contrast, the outcomes of biologics treatment have been more varied. However, to establish a clearer understanding of which specific pathways to target for a more effective approach to vitiligo, additional in vitro studies and extensive clinical research involving a larger population are imperative.

show abstract

Segmental vitiligo following acitretin treatment for infantile generalized pustular psoriasis resulting in repigmentation under secukinumab therapy

Cited by 2 publications

References 9 publications

The update of treatment strategies in pediatrics with generalized pustular psoriasis in China

The update of treatment strategies in pediatrics with generalized pustular psoriasis in China

Updates on Potential Therapeutic Approaches for Vitiligo: Janus Kinase Inhibitors and Biologics

Contact Info

Product

Resources

About